Distinctive cellular response to aluminum based adjuvants

Area of Science:

• Immunology
• Vaccinology
• Cell Biology

Background:

• Aluminum-based adjuvants (ABAs) enhance vaccine immunogenicity.
• A hypothesis suggests necrotic cell stress signals contribute to ABA effectiveness.
• The cellular origin and adjuvant composition's role in ABA-induced necrosis is unclear.

Purpose of the Study:

• To investigate if aluminum adjuvant-induced necrosis is similar across different cell types.
• To evaluate the impact of commercially available ABAs on human macrophages and astrocytes.
• To assess cell viability, reactive oxygen species (ROS), and cytokine production (TNF-α, IL-6).

Main Methods:

• Human macrophages (THP-1) and primary astrocytes were exposed to three ABAs (Alhydrogel, Imject alum, Adju-Phos) and alum.
• Cells were treated with varying adjuvant concentrations (10-100 μg/mL) for 24 or 72 hours.
• Quantification of cell viability, ROS formation, TNF-α, and IL-6 levels.

Main Results:

• FDA-approved adjuvants (Alhydrogel, Adju-Phos) reduced cell viability in both cell types.
• At 72 hours, decreased viability correlated with increased ROS formation.
• Astrocytes and macrophages exhibited distinct cytokine secretion profiles post-ABA exposure.

Conclusions:

• Aluminum adjuvants induce differential responses in macrophages and astrocytes.
• Cellular origin influences the immune response to ABAs.
• Adjuvant efficacy in vaccine design requires careful consideration of cell-type specific activation.